Ri Xiang Kong
Chief Tech/Sci/R&D Officer at Beijing Biostar Pharmaceuticals Co. Ltd.
Profile
Ri Xiang Kong is a Member-Supervisory Board at Beijing Biostar Pharmaceuticals Co. Ltd.
since 2003.
He graduated from Tianjin University of Science & Technology in 2002.
Ri Xiang Kong active positions
| Companies | Position | Start |
|---|---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
 Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Chief Tech/Sci/R&D Officer | 30/11/2018 |
Training of Ri Xiang Kong
| Tianjin University of Science & Technology | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Health Technology |
- Stock Market
- Insiders
- Ri Xiang Kong
